CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

NDA 21153/S-048

Trade Name: **NEXIUM**

Generic Name: **Esomeprazole Magnesium**

Sponsor: **AstraZeneca LP**

Approval Date: 02/14/2014

Indications: NEXIUM is a proton pump inhibitor indicated for the following:

- Treatment of gastroesophageal reflux disease (GERD)
- Risk reduction of NSAID-associated gastric ulcer
- H. pylori eradication to reduce the risk of duodenal ulcer recurrence
- Pathological hypersecretory conditions, including Zollinger-Ellison syndrome

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 21153/S-048

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	**X**
Other Action Letters	
Labeling	
Summary Review	
Officer/Employee List	
Office Director Memo	
Cross Discipline Team Leader Review	
Medical Review(s)	
Chemistry Review(s)	**X**
Environmental Assessment	
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/Biopharmaceutics Review(s)	
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	
Other Review(s)	
Administrative/Correspondence Document(s)	**X**

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 21153/S-048

APPROVAL LETTER

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21153/S-048

APPROVAL LETTER

AstraZeneca LP
Attention: Judy W. Firor
Regulatory Affairs Director
1800 Concord Pike, P.O. Box 8355
Wilmington, DE 19803-8355

Dear Ms. Firor:

Please refer to your Supplemental New Drug Application (sNDA) dated August 28, 2013, received August 28, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Nexium® (esomeprazole magnesium) Delayed-Release Capsules.

This "Changes Being Effected in 30 days" supplemental new drug application provides for the addition of AstraZeneca Pharmaceuticals LP (Newark, NJ) as a packaging and release site of the drug product, including a change of bottle for that site.

We have completed our review of this supplemental new drug application. This supplement is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Cathy Tran-Zwanetz, Regulatory Project Manager, at (301) 796-3877.

Sincerely,

{See appended electronic signature page}

Thomas F. Oliver, Ph.D.
Branch Chief, Branch VI
Division of New Drug Quality Assessment II
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THOMAS F OLIVER
02/14/2014

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 21153/S-048

CHEMISTRY REVIEW(S)

CHEMISTS REVIEW Jeffrey B. Medwid, Ph.D.	1. ORGANIZATION	2. NDA NUMBER
	ONDQA Div II, Branch VI and CDER/ODEIII/DGIEP	21-153
3. NAME AND ADDRESS OF APPLICANT		4. COMMUNICATION, DATE
ASTRAZENECA LP 1800 CONCORD PIKE PO BOX 8355 WILMINGTON, DELAWARE 198038355 UNITED STATES		**S-048; CBE-30** Letter Date: August 28, 2013 Received Date: August 28, 2013 PDUFA DATE: February 28, 2014 Type: PAC-ATLS
5. PROPRIETARY NAME	6. NAME OF THE DRUG	7. AMENDMENTS, REPORT, DATE
Nexium 20/40 DRC Capsules	Esomeprazole magnesium	None
8.SUPPLEMENT PROVIDES FOR:		
the addition of AstraZeneca Pharmaceuticals LP (Newark, NJ) as a packaging and release site of Nexium Delayed-Release Capsules, 20 and 40 mg, including a change of bottle for that site.		
9. PHARMACOLOGICAL CATEGORY	10. HOW DISPENSED	11. RELATED IND, NDA, DMF & CONSULT REVIEWS
Gastric acid secretion inhibitor	Rx	
12. DOSAGE FORM	13. POTENCY	
Capsules	20 mg	
14. CHEMICAL NAME AND STRUCTURE		

NEXIUM®

5-Methoxy-2-[(*S*)-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]benzimidazole, magnesium salt (2:1), trihydrate

$C_{34}H_{36}MgN_6O_6S_2 \cdot 3H_2O$. 767.17.



15. COMMENTS

CBE-30: provides for the addition of AstraZeneca Pharmaceuticals LP (Newark, NJ) as a packaging and release site of Nexium Delayed-Release Capsules, 20 and 40 mg, including a change of bottle for that site.

To register AstraZeneca Pharmaceuticals LP (Newark, NJ) as a packaging and release site of Nexium Delayed-Release Capsules the applicant must demonstrate it has met the requirements set forth in 1998 Guidance for Industry: PAC-ATLS: Post-Approval Changes- Analytical Testing Laboratory Sites (PAC-ATLS).

1. The test methods approved in the application or methods that have been implemented under 21 CFR 314.70(d) will be used.
2. All post approval commitments made by the applicant relating to the currently approved test methods have been fulfilled.
3. The new testing facility has the capability to perform the intended testing (see **Attachment 1** for the information of the new site)
4. The new testing facility has had a satisfactory current good manufacturing practice inspection within the past two years (see **Attachment 3** of this review for the OC EES Summary recommending approval of the site).

All of the requirements set forth in 1998 Guidance for Industry: PAC-ATLS: Post-Approval Changes-Analytical Testing Laboratory Sites (PAC-ATLS) have been met as stated in the Applicant's Justification of Change (see Attachment 1 of this review).

Note: The bottles used at AstraZeneca Pharmaceuticals LP, Newark, US will be different in regards to the ones used at Merck Sharp & Dohme Corp. The 30 and 90 count bottles used at AstraZeneca Pharmaceuticals LP, Newark, US will be square shaped instead of round shaped. (b) (4) For present and proposed bottle configurations please see Table 2 and Table 3. For more details regarding the container closure systems please see Table 4. See *Attachment 2: for Tables 2, 3 and 4.*

Reviewer Comments: These bottle changes pose no safety risk to the product and are all **acceptable**.

Based on the acceptable reviewer comments on the bottle change and since the site meets the criteria established by the PAC-ATLS guidelines and the OC has provided an overall acceptable recommendation based on District Recommendation on September 9, 2013. This supplement is recommended for approval from a CMC standpoint.

Based on the acceptable recommendation by this reviewer on both key issues to this review this supplement is recommended for approval from a CMC point of view.

16. CONCLUSION AND RECOMMENDATION		
This supplement is recommended for approval from a CMC perspective.		
17. NAME	**18. REVIEWERS SIGNATURE**	**19. DATE COMPLETED**
Jeffrey B. Medwid	See appended electronic signature sheet	February 14, 2014

5 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page

---

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JEFFREY B MEDWID
02/14/2014

THOMAS F OLIVER
02/14/2014

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 21153/S-048

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21153/S-048

CBE SUPPLEMENT – ACKNOWLEDGEMENT

AstraZeneca LP
Attention: Judy W. Firor
Regulatory Affairs Director
1800 Concord Pike, P.O. Box 8355
Wilmington, DE 19803

Dear Ms. Firor:

We have received your Supplemental New Drug Application (sNDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA or the Act) for the following:

NDA NUMBER:	21153
SUPPLEMENT NUMBER:	S-048
PRODUCT NAME:	Nexium® (esomeprazole magnesium) Delayed-released Capsule
DATE OF SUBMISSION:	August 28, 2013
DATE OF RECEIPT:	August 28, 2013

This supplemental application, submitted as a "Changes Being Effected in 30 days" supplement, proposes the addition of AstraZeneca Pharmaceuticals LP, Newark, USA, as a packaging and release site of drug product, including change of bottle for that site.

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on October 27, 2013, in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be February 28, 2014.

Cite the application number listed above at the top of the first page of all submissions to this application. Send all submissions, electronic or paper, including those sent by overnight mail or courier, to the following address:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Gastroenterology and Inborn Errors Products
5901-B Ammendale Road
Beltsville, MD 20705-1266

All regulatory documents submitted in paper should be three-hole punched on the left side of the page and bound. The left margin should be at least three-fourths of an inch to assure text is not obscured in the fastened area. Standard paper size (8-1/2 by 11 inches) should be used; however, it may occasionally be necessary to use individual pages larger than standard paper size. Non-standard, large pages should be folded and mounted to allow the page to be opened for review without disassembling the jacket and refolded without damage when the volume is shelved. Shipping unbound documents may result in the loss of portions of the submission or an unnecessary delay in processing which could have an adverse impact on the review of the submission. For additional information, see http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/DrugMasterFilesDMFs/ucm073080.htm.

If you have questions, call me, at (301) 796-3877.

Sincerely,

{See appended electronic signature page}

Cathy Tran-Zwanetz
Regulatory Health Project Manager
Division of New Drug Quality Assessment II
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

CATHERINE A TRAN-ZWANETZ
09/30/2013